Serum-free conditioned media (24 h) was placed on the bottom chamber of a transwell plate (Sigma-Aldrich, #CLS3421). Jurkat-CXCR3 cells (5×105) were plated in the top chamber and cells migrating to the bottom chamber after 4 h were counted using a Z2 coulter counter analyzer (Beckman Coulter). An antibody neutralizing CCL5 (R&D systems, #MAB678-SP), CXCL10 (R&D systems, #MAB266-SP) CXCL11 (R&D systems, #MAB672-SP), IFN alpha (R&D systems, #211001), or IFN beta (R&D systems, #MAB814-SP) was added to the CM in the bottom chamber.
Mab678 sp
Manufactured by R&D Systems
MAB678-SP is a monoclonal antibody that specifically recognizes and binds to a target antigen. It is intended for use in research applications.
Automatically generated - may contain errors
Lab products found in correlation
Z2 coulter counter analyzer, by Beckman Coulter (1 mentions)
Cls3421, by Merck Group (1 mentions)
Mab672 sp, by R&D Systems (1 mentions)
Recombinant human ccl5, by R&D Systems (1 mentions)
Met rantes, by R&D Systems (1 mentions)
H1299, by National Collection of Authenticated Cell Cultures (1 mentions)
2 protocols using mab678 sp
1
Chemokine-mediated Jurkat cell migration
2
Lung Cancer Cell Sensitization to Chemotherapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NSCLC A549 (lung adenocarcinoma) and H1299 (lung large cell carcinoma) cell lines were purchased from the China Center for Type Culture Collection, and cultivated in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator with 5% CO2 at 37°C. Cells in the logarithmic growth phase were used for all experiments.
For cell treatment, cancer cells were incubated with CAF-CM or NF-CM in combination with either anti-CCL5 antibody (0.1 µg/ml; cat. no. MAB678-SP; R&D Systems, Inc.), CCR5 antagonist (Met-RANTES; 0.1 µg/ml; cat. no. 335-RM-025; R&D Systems, Inc.) or recombinant human CCL5 (3 ng/ml; cat. no. 300-06; PeproTech, Inc.) for 6 h, followed by treatment with 50 µM DDP (Sigma-Aldrich; Merck KGaA) in the presence of CM for another 48 h.
For cell treatment, cancer cells were incubated with CAF-CM or NF-CM in combination with either anti-CCL5 antibody (0.1 µg/ml; cat. no. MAB678-SP; R&D Systems, Inc.), CCR5 antagonist (Met-RANTES; 0.1 µg/ml; cat. no. 335-RM-025; R&D Systems, Inc.) or recombinant human CCL5 (3 ng/ml; cat. no. 300-06; PeproTech, Inc.) for 6 h, followed by treatment with 50 µM DDP (Sigma-Aldrich; Merck KGaA) in the presence of CM for another 48 h.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!